Literature DB >> 34276212

Doxorubicin-Bound Hydroxyethyl Starch Conjugate Nanoparticles with pH/Redox Responsive Linkage for Enhancing Antitumor Therapy.

Ronghua Tan1, Danlei Tian1, Jiaoyan Liu1, Congcong Wang1, Ying Wan1.   

Abstract

BACKGROUND: Chemotherapeutic drugs used for tumor treatments often show limited efficiency due to their short lifetime, nonspecific delivery, and slow or insufficient intracellular drug release, and also, they can cause severe system or organ toxicity. The development of chemotherapeutic nanomedicines with high efficacy and satisfactory safety still remains a challenge for current tumor chemotherapy.
METHODS: A novel type of conjugate was synthesized using hydroxyethyl starch (HES) as a carrier while binding doxorubicin (DOX) onto HES backbone through a pH/redox responsive linker containing both disulfide and hydrazone bonds in series. The built conjugates were self-assembled into nanoparticles (NPs) (HES-SS-hyd-DOX NPs) for achieving enhanced antitumor therapy and adequate safety.
RESULTS: HES-SS-hyd-DOX NPs had a certain ability for the tumor-orientated drug accumulation and were capable of releasing DOX itself rather than DOX derivatives. It was found that the pH/redox responsive linkage enabled the NPs to achieve fast and sufficient intracellular drug release. Based on the tumor-bearing mouse model, antitumor results demonstrated that these NPs were able to inhibit the growth of the advanced tumors with significantly enhanced efficacy when compared to free DOX, and to those conjugate NPs containing only a single responsive or unresponsive bond. Besides, HES-SS-hyd-DOX NPs also showed adequate safety to the normal organs of the treated mice.
CONCLUSION: The pH/redox responsive linkage in HES-SS-hyd-DOX was found to play a critical role in mediating the drug accumulation and the fast and sufficient intracellular drug release. The HES-exposed surface of HES-SS-hyd-DOX NPs endowed the NPs with long circulation capability and remarkably reduced the DOX-induced side effects.
© 2021 Tan et al.

Entities:  

Keywords:  antitumor therapy; conjugate nanoparticles; doxorubicin; hydroxyethyl starch; pH/redox responsive linkage

Mesh:

Substances:

Year:  2021        PMID: 34276212      PMCID: PMC8277972          DOI: 10.2147/IJN.S314705

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


  50 in total

Review 1.  Hydroxyethyl starch: a review of pharmacokinetics, pharmacodynamics, current products, and potential clinical risks, benefits, and use.

Authors:  Polly A Glover; Elke Rudloff; Rebecca Kirby
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2014-08-26

Review 2.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.

Authors:  Jun Fang; Hideaki Nakamura; Hiroshi Maeda
Journal:  Adv Drug Deliv Rev       Date:  2010-05-02       Impact factor: 15.470

Review 3.  Drug penetration in solid tumours.

Authors:  Andrew I Minchinton; Ian F Tannock
Journal:  Nat Rev Cancer       Date:  2006-08       Impact factor: 60.716

4.  Targeted hydroxyethyl starch prodrug for inhibiting the growth and metastasis of prostate cancer.

Authors:  Kaidong Zhao; Di Li; Weiguo Xu; Jianxun Ding; Weiqian Jiang; Mingqiang Li; Chunxi Wang; Xuesi Chen
Journal:  Biomaterials       Date:  2016-11-23       Impact factor: 12.479

5.  α-Amylase- and Redox-Responsive Nanoparticles for Tumor-Targeted Drug Delivery.

Authors:  Yihui Li; Hang Hu; Qing Zhou; Yanxiao Ao; Chen Xiao; Jiangling Wan; Ying Wan; Huibi Xu; Zifu Li; Xiangliang Yang
Journal:  ACS Appl Mater Interfaces       Date:  2017-05-30       Impact factor: 9.229

Review 6.  Drug resistance and the solid tumor microenvironment.

Authors:  Olivier Trédan; Carlos M Galmarini; Krupa Patel; Ian F Tannock
Journal:  J Natl Cancer Inst       Date:  2007-09-25       Impact factor: 13.506

Review 7.  pH-sensitive polymeric nanoparticles for tumor-targeting doxorubicin delivery: concept and recent advances.

Authors:  Fenghua Meng; Yinan Zhong; Ru Cheng; Chao Deng; Zhiyuan Zhong
Journal:  Nanomedicine (Lond)       Date:  2014-03       Impact factor: 5.307

Review 8.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.

Authors:  Nicolas Bertrand; Jun Wu; Xiaoyang Xu; Nazila Kamaly; Omid C Farokhzad
Journal:  Adv Drug Deliv Rev       Date:  2013-11-22       Impact factor: 15.470

Review 9.  Recent advances in the development of nanoparticles for multimodality imaging and therapy of cancer.

Authors:  Mei Liu; Redmond-Craig Anderson; Xiaoli Lan; Peter S Conti; Kai Chen
Journal:  Med Res Rev       Date:  2019-10-25       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.